LivaNova PLC (Nasdaq: LIVN), a global medical technology company headquartered in London, has elected Jette Nygaard-Andersen to its Board of Directors following its Annual General Meeting on June 10.
The appointment brings a seasoned executive with more than 25 years of leadership experience in highly regulated international businesses to the board.
William Kozy, Chair of LivaNova’s Board, expressed enthusiasm for the new addition, highlighting her breadth of experience across complex global organisations.
“We’re pleased to welcome Jette to LivaNova’s Board,” said Kozy. “She brings deep medtech governance expertise, proven CEO leadership, and a strong track record of transformation, strategic M&A, and digital innovation across complex global businesses.”
Kozy added that “her international and public company board experience will be a valuable addition to LivaNova,” underscoring the strategic rationale behind the appointment.
Nygaard-Andersen currently serves as Chair of the Board for Coloplast A/S, a global medical device company based in Denmark, where she has been a Non-Executive Director since 2015.
Her previous roles include serving as Chief Executive Officer and Executive Director of Entain plc, where she led a comprehensive business transformation and delivered significant growth for the global sports betting and gaming company.
Prior to Entain, Nygaard-Andersen spent 16 years at Modern Times Group AB, a Nasdaq Nordic-listed European media, entertainment, and gaming group, progressing through senior executive positions including Chief Operating Officer and CEO of multiple business units.
She holds a Master of Science degree in Business Administration, with a concentration in Finance, from the University of Copenhagen, adding strong academic grounding to her extensive executive track record.
Nygaard-Andersen expressed confidence in the company’s direction, stating: “LivaNova has a strong foundation and a clear strategic path forward. I look forward to working with the Board and management team to support the Company’s continued growth and impact as it advances innovative medical technologies that improve the lives of patients worldwide.”
Concurrent with the new appointment, Dr. Sharon O’Kane stepped down from the Board after deciding not to seek re-election, having served as a director since the formation of LivaNova in 2015.
“We are deeply grateful to Sharon for her many important contributions to the Company during more than a decade of distinguished and dedicated service,” Kozy said, noting her lasting impact on the business.
O’Kane had served as Chair of the Nominating and Corporate Governance Committee since 2017 and as Lead Independent Director between 2023 and 2024, guiding LivaNova through numerous key milestones.
Brooke Story, appointed to the Board in 2022, will succeed O’Kane as Chair of the Nominating and Corporate Governance Committee, serving alongside Nygaard-Andersen, Chris Barry, and Stacy Enxing Seng.
Peter Wilver will assume the role of Chair of the Compensation and Human Capital Management Committee, while Todd Schermerhorn will remain Chair of the Audit and Compliance Committee, and Kozy will continue as Chair of the Board.
LivaNova, with approximately 3,300 employees and a presence in more than 100 countries, focuses on neurological and cardiac medical solutions and has operated for nearly five decades.